Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Munetaka Tokumasu

Tamotsu Suzuki

Koji Ohsumi

Tadakiyo Nakagawa

Takahiro Koshiba

Tatsuhiro Yamada

Kayo Matsumoto

Masayuki Sugiki

Yoichiro Shima

Taisuke Ichimaru

Itsuya Tanabe

Misato Noguchi

Atsushi Konishi

Osamu Ikehara

Yuko Kodama

Akira Nakayama

Hideki Matsumoto

Yasuhiro Tanaka

Tatsuya Okuzumi

Naoyuki Fukuchi

Noriyasu Kataoka

Kazuyuki Sagi

Mitsuo Takahashi

Koichi Fujita

Shunsuke Kageyama

Yuki Kajigaya

Kenji Shinkai

Ayatoshi Andou

Hajime Ito

Yoriko Yamamoto

Kazuyuki Ubukata

Kazuyoshi Takahashi

Takashi Tsuji

Toshihiko Yoshimura

Manabu Kitazawa

Morikazu Kito

Kaoru Yoshida

Shingo Makino

Sayaka Asari

Akira Takahara

Takashi Kayahara

Tomoko Takeda

Yukitsugu Ono

Shinichi Fujita

Tetsuo Yano

Masataka Shoji

Hajime Koganei

Shunji Takehana

Wataru Miyanaga

Sen Takeshita

Kuniya Sakurai

Katsutoshi Sakata

Masaki Hashimoto

Kaori Kobayashi

Tomomi Yoshida

Youji Yamada

Ayatoshi Ando

Haruko Hirashima

Yuki Saitou

Akiko Oonuki

Hiroki Inoue

Kazumi Tashiro

Shigeo Hirasawa

Masatsugu Noguchi

Atsushi Tsuruta

Nobuhiko Hayakawa

Yui Yamaura

Junko Ezaki

Akira Nakajo

Mizuki Kawahira

Kana Iwasaki

Yasuko Nogi

Provided is a compound having &#x3b1;4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where Rto R, e to h, D, and B represent those as described in the specification.

Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Heteroarylcarboxylic acid ester derivative

The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I) wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.

Heterocyclic carboxylic acid ester derivative

Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe.  In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Aris represented by any one of the following rings and the like. 

Pharmaceutical composition for treating diabetes

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification,are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes. 

Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1;4 integrin.

Phenylalanine derivatives

The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

Aniline derivatives

The present invention provides a piperidine derivative represented by the following formula or analogs thereto, which are used for agents for treating or preventing various diseases related to 5-HT7. 

Piperidine derivative

The present invention provides dihydrodiaryloxazepine derivative represented by the following formula [1], analogs thereof and pharmaceutical compositions containing them. Those compounds have an excellent effect of improving functional diseases of gastrointestinal tracts 

Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same

The present invention provides benzodiazepine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of inhibiting activated blood-coagulation factor X. These compounds are usable as agents for treating various diseases concerned with the activated blood-coagulation factor X.

Benzodiazepine derivatives

Growing community of inventors

Kawasaki, Japan

Munetaka Tokumasu